Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures

BMC Nephrology

Table 1 Results of laboratory test Upon admission, (May 26^th, 2016), on admission (Oct 9^th, 2019) and the latest follow-up (May 27^th, 2021)

Component	Jan 16^th, 2018 (Upon admission)	Oct 9^th, 2019 (On admission)	May 27^th, 2021 (Latest follow-up)
Urinalysis results
Urinary protein	negative	4+	2+
24-HTP	ND	4.6	ND
Peripheral blood
HB (g/L)	143	138	98
WBC (×10⁹/L)	6.38	11.78	3.43
PLT (×10⁹/L)	169	126	65
Chemistries
CREA (μmol/L)	45	91	106
BUN (mmol/L)	4.6	8.3	8.6
eGFR (ml/min/1.73 m²)	104.6	58.7	48.3
Bilirubin (μmol/L)	14.7	7.6	6.2
LDH (IU/L)	197	249	298
TP (g/L)	74.5	51.7	56.9
ALB (g/L)	47.7	29.1	33.9
TG (mmol/L)	ND	3.19	2.25
CHOL (mmol/L)	ND	9.09	6.29
Other
CRP (mg/L)	ND	11.5	ND
PCT (ng/ml)	ND	0.16	ND
Coombs Test	ND	negative	ND
ADAMTS-13	ND	negative	ND
THSD7A	ND	negative	ND

Note: 24hHTP 24-hour urine protein, HB Hemoglobin, WBC White blood cell, PLT Platelets, CREA Creatinine, BUN Blood urea nitrogen, LDH Lactic dehydrogenase, TP Total protein, ALB Albumin, TG Triglyceride, CHOL Cholesterol, eGFR Estimate glomerular filtration rate, CRP C-reactive protein, PCT Procalcitonin, Coombs Test A test to detect non-agglutinating antibodies against erythrocytes by use of anti-antibodies (the Coombs’ reagent), ADAMTS-13 A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, THSD7A Thrombospondin type 1 domain–containing 7A, ND No data

ISSN: 1471-2369